Results 91 to 100 of about 19,015 (246)

Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia

Saudi Pharmaceutical Journal
Introduction: Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA), is often prescribed for managing type 2 diabetes, particularly in cases unresponsive to other hypoglycemic agents.
Yazed AlRuthia, Khaled Hani Aburisheh, Sondus Ata, Raghad Bin Salleeh, Shahad B. Alqudhibi, Raghad B. Alqudhibi, Ziad Alkraidis, Hala Humood Alkhalaf, Abdulrahman Abdullah Almogirah, Muhammad Mujammami, Reem Al Khalifah   +10 more
doaj   +1 more source

Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction‐associated steatotic liver disease treated with semaglutide: A case series

JPGN Reports, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects 30%–40% of youth with obesity and lacks approved pharmacologic therapies. In this single‐center retrospective case series at a tertiary care safety‐net children's hospital, we evaluated five adolescents (mean age: 17.0 years; 100% Hispanic; 60% male; mean body mass index:
Rachel Schenker, Katya Fomenko, Fotini T. Mitsinikos, Alaina P. Vidmar   +3 more
wiley   +1 more source

Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis

Frontiers in Pharmacology
ObjectiveThe incidence of ischemic cardiomyopathy increases annually worldwide, and it is the leading cause of mortality in China. Although interventional diagnostic and therapeutic techniques can promptly open the culprit vessels, myocardial ischemia ...
Yan Liu, Zixuan Li, Xinhe Xu, Yan Zou, Miaomiao Zhang, Yingyu Chen, Wenwu Zhu, Bing Han   +7 more
doaj   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source

Highly Reproducible, Vendor‐Agnostic, Motion‐Insensitive Liver PDFF Mapping at 0.55T, 1.5T, and 3T

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose To develop and validate a vendor‐agnostic, motion‐insensitive proton‐density fat‐fraction (PDFF) quantification method. Methods Flip‐angle‐modulated (FAM) 2D chemical‐shift‐encoded (CSE) MRI for PDFF quantification was implemented in both the vendor‐agnostic platform Pulseq (“Pulseq‐FAM”) and one vendor‐specific platform (“GE‐specific ...
Jiayi Tang, Daiki Tamada, Jon‐Fredrik Nielsen, Jitka Starekova, Julius F. Heidenreich, Felix Schön, Alexandra A. Anagnostopoulos, Amirhossein Roshanshad, Lu Mao, Shohei Fujita, Pengcheng Xu, Christopher Keen, Imam Ahmed Shaik, Eugene Milshteyn, Seonghwan Yee, Andrew J. Ellison, David Rutkowski, Jeff Kammerman, Jean H. Brittain, Xiaodong Zhong, William A. Grissom, Maxim Zaitsev, Aaron L. Carrel, Yogesh Rathi, Yun Jiang, Berkin Bilgic, Scott B. Reeder, Diego Hernando   +27 more
wiley   +1 more source

Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice

Frontiers in Pharmacology
BackgroundThe purpose of this study was to explore how semaglutide, a GLP-1RA, regulates serum metabolism and gut microbiota to improve obesity in mice and whether fecal microbiota transplantation (FMT) can transmit the beneficial effects of semaglutide ...
Luyan Sun, Bingqing Shang, Suyuan Lv, Guolong Liu, Qiu Wu, Yue Geng   +5 more
doaj   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source